WO2013088369A3 - Use of the protein mmp-12 in the prevention and/or treatment of greasy skin and/or greasy-prone skin - Google Patents

Use of the protein mmp-12 in the prevention and/or treatment of greasy skin and/or greasy-prone skin Download PDF

Info

Publication number
WO2013088369A3
WO2013088369A3 PCT/IB2012/057238 IB2012057238W WO2013088369A3 WO 2013088369 A3 WO2013088369 A3 WO 2013088369A3 IB 2012057238 W IB2012057238 W IB 2012057238W WO 2013088369 A3 WO2013088369 A3 WO 2013088369A3
Authority
WO
WIPO (PCT)
Prior art keywords
greasy
skin
polypeptide
seq
prevention
Prior art date
Application number
PCT/IB2012/057238
Other languages
French (fr)
Other versions
WO2013088369A2 (en
Inventor
Isabelle Castiel
Audrey Gueniche
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of WO2013088369A2 publication Critical patent/WO2013088369A2/en
Publication of WO2013088369A3 publication Critical patent/WO2013088369A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to the cosmetic use of an effective amount of at least one active agent consisting of a polypeptide having at least 80% amino acid identity with a metalloprotease MMP-12 whose sequence is chosen from SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 indicated below, or a C-terminal fragment of this polypeptide, for preventing and/or treating greasy skin and/or greasy-prone skin, the said polypeptide or the said fragment comprising the sequence KDXK, in which X represents aspartic acid or glutamic acid.
PCT/IB2012/057238 2011-12-14 2012-12-12 Use of the protein mmp-12 in the prevention and/or treatment of greasy skin and/or greasy-prone skin WO2013088369A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1161619 2011-12-14
FR1161619A FR2984127A1 (en) 2011-12-14 2011-12-14 USE OF PROTEIN MMP-12 IN THE PREVENTION AND / OR TREATMENT OF OIL AND / OR FATTY SKIN.
US201261604222P 2012-02-28 2012-02-28
US61/604,222 2012-02-28

Publications (2)

Publication Number Publication Date
WO2013088369A2 WO2013088369A2 (en) 2013-06-20
WO2013088369A3 true WO2013088369A3 (en) 2014-01-23

Family

ID=46229531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/057238 WO2013088369A2 (en) 2011-12-14 2012-12-12 Use of the protein mmp-12 in the prevention and/or treatment of greasy skin and/or greasy-prone skin

Country Status (2)

Country Link
FR (1) FR2984127A1 (en)
WO (1) WO2013088369A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087325A2 (en) * 2002-04-08 2003-10-23 The Brigham And Women's Hospital, Inc. Methods and compositions for preventing and treating microbial infections
WO2009111083A2 (en) * 2008-03-06 2009-09-11 Halozyme, Inc. In vivo temporal control of activ at able matrix- degrading enzymes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW508247B (en) 1997-03-31 2002-11-01 Shiseido Co Ltd Cosmetic or dermatological topical composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087325A2 (en) * 2002-04-08 2003-10-23 The Brigham And Women's Hospital, Inc. Methods and compositions for preventing and treating microbial infections
WO2009111083A2 (en) * 2008-03-06 2009-09-11 Halozyme, Inc. In vivo temporal control of activ at able matrix- degrading enzymes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOJAR R A ET AL: "Acne and propionibacterium acnes", CLINICS IN DERMATOLOGY, J.B. LIPPINCOTT, PHILADELPHIA, PA, US, vol. 22, no. 5, September 2004 (2004-09-01), pages 375 - 379, XP004647106, ISSN: 0738-081X, DOI: 10.1016/J.CLINDERMATOL.2004.03.005 *
DEL ROSSO JQ AND KIM GK: "Seborrheic Dermatitis and Malassezia species", JOURNAL OF CLINIC AND AESTHETIC DERMATOLOGY, vol. 2, no. 111, November 2009 (2009-11-01), pages 14 - 17, XP002680812 *

Also Published As

Publication number Publication date
FR2984127A1 (en) 2013-06-21
WO2013088369A2 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
MX360208B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX363136B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX357505B (en) Medicinal composition for treating and/or preventing cancer.
MX2012008999A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340015B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX342291B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
EA201490809A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NON-EFFECTIVE ERYTHROPOESIS
NZ711037A (en) Peptides and compositions for treatment of joint damage
UA111141C2 (en) Recombinant antigen of rsv
MX351414B (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
NZ623576A (en) Tfpi inhibitors and methods of use
MX2014001375A (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer.
MX2008009493A (en) Novel peptide and use thereof.
PE20140617A1 (en) ACID ALPHA GLUCOSIDASE MODIFIED WITH ACCELERATED PROCESSING
WO2019045248A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
NZ610389A (en) Use of a composition comprising an antimicrobial peptide as a food preservative
NZ708091A (en) Stabilized insulin-like growth factor polypeptides
WO2006135493A3 (en) A composition for wound healing and use thereof
WO2013088371A3 (en) Use of the mmp-12 protein in the prevention and/or treatment of dandruff conditions of the scalp
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
MX2018008545A (en) An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition.
HK1121383A1 (en) Wound healing agent and composition
MX2017013480A (en) Pharmaceutical composition for treating and/or preventing cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815835

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12815835

Country of ref document: EP

Kind code of ref document: A2